XTL Biopharmaceuticals
XTLB
3 hedge funds and large institutions have $678K invested in XTL Biopharmaceuticals in 2022 Q2 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 1 closing their positions.
0% less ownership
Funds ownership: 0.02% → 0.02% (-0%)
25% less funds holding
Funds holding: 4 → 3 (-1)
35% less capital invested
Capital invested by funds: $1.05M → $678K (-$368K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$2K |
| 2 |
Morgan Stanley
New York
|
-$970 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
NC
1
Noked Capital
Tel Aviv,
Israel
| $302K | – | – | – |
|
|
NI
2
Noked Israel
Ramat Hasharon,
Israel
| $302K | – | – | – |
|
|
3
Morgan Stanley
New York
| $74K | -$970 | -125 | -1% |
|
|
4
UBS Group
Zurich,
Switzerland
| – | -$2K | -203 | Closed |
|
XTLB Hedge Fund Activity: Q2 2022 in Review
3 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in XTL Biopharmaceuticals (XTLB) for Q2 2022, worth a combined $678K — down 35% from $1.05M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of XTLB and 0 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 0 added.
The largest seller was UBS Group, exiting entirely with an estimated $2K sold.
- 3 institutional investors held XTL Biopharmaceuticals (XTLB) as of Q2 2022, down from 4 in Q1 2022.
- Funds reported $678K of XTL Biopharmaceuticals stock for Q2 2022, down 35% quarter-over-quarter.
- 0 funds opened new XTL Biopharmaceuticals positions in Q2 2022 and 1 closed out, a net change of -1 holder.
- The largest XTL Biopharmaceuticals seller in Q2 2022 was UBS Group, an estimated $2K sold.
Based on aggregated 13F filings for Q2 2022.